Your browser is no longer supported. Please, upgrade your browser.
SAGE Sage Therapeutics, Inc. daily Stock Chart
Sage Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.87 Insider Own0.80% Shs Outstand39.97M Perf Week-3.00%
Market Cap6.49B Forward P/E- EPS next Y-8.21 Insider Trans-15.80% Shs Float39.53M Perf Month89.91%
Income-256.60M PEG- EPS next Q-1.98 Inst Own- Short Float9.19% Perf Quarter158.88%
Sales- P/S- EPS this Y-39.50% Inst Trans2.30% Short Ratio3.94 Perf Half Y93.47%
Book/sh5.34 P/B30.40 EPS next Y-11.10% ROA-78.90% Target Price202.29 Perf Year231.33%
Cash/sh6.09 P/C26.64 EPS next 5Y- ROE-89.50% 52W Range44.55 - 173.36 Perf YTD217.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-6.37% Beta2.90
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low264.35% ATR10.58
Employees135 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)77.96 Volatility5.40% 5.51%
OptionableYes Debt/Eq0.00 EPS Q/Q-71.60% Profit Margin- Rel Volume1.27 Prev Close158.03
ShortableYes LT Debt/Eq0.00 EarningsFeb 01 BMO Payout- Avg Volume921.85K Price162.32
Recom1.60 SMA2043.99% SMA5089.11% SMA200111.02% Volume1,177,180 Change2.71%
Dec-08-17Reiterated Needham Buy $100 → $193
Dec-08-17Reiterated Canaccord Genuity Buy $140 → $191
Dec-07-17Reiterated Chardan Capital Markets Buy $140 → $225
Nov-10-17Upgrade Chardan Capital Markets Neutral → Buy $60 → $140
Nov-10-17Reiterated Needham Buy $86 → $100
Oct-06-17Resumed Goldman Buy $87
Sep-15-17Initiated RBC Capital Mkts Outperform $117
Sep-13-17Reiterated Needham Buy $95 → $86
Aug-09-17Resumed Stifel Buy $104
May-16-17Initiated Needham Buy $82
May-12-17Initiated BofA/Merrill Buy $85
Feb-22-17Downgrade H.C. Wainwright Buy → Neutral $56 → $76
Feb-14-17Upgrade Chardan Capital Markets Sell → Neutral $60
Dec-14-16Upgrade Raymond James Outperform → Strong Buy $84
Nov-14-16Initiated Stifel Buy $90
Oct-04-16Resumed Leerink Partners Outperform $68
Sep-13-16Initiated Raymond James Outperform $75
Jun-23-16Initiated H.C. Wainwright Buy $56
May-24-16Initiated Chardan Capital Markets Sell $18
Mar-30-16Initiated Goldman Neutral
Dec-14-17 09:51AM  10 Biggest Antidepressant Drug Companies In 2017 Insider Monkey
Dec-13-17 07:31AM  5 Biotech Buyout Candidates for 2018 Motley Fool
06:00AM  Why Biotech Sage Therapeutics May Keep Soaring Investopedia
Dec-11-17 08:36AM  Sage Therapeutics Soars: Stock Adds 7.1% in Session Zacks
Dec-08-17 04:59PM  Why Chicago Bridge & Iron, Teva Pharmaceutical Industries, and Sage Therapeutics Jumped Today Motley Fool +7.08%
03:42PM  Gene therapy stocks to watch CNBC Videos
01:33PM  Sage CEO hopes experimental depression drug will be as big as Prozac CNBC
01:23PM  Sage Therapeutics takes on major depressive disorder CNBC Videos
08:34AM  Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Sage Therapeutics and Nektar Therapeutics ACCESSWIRE
07:38AM  Sage Therapeutics shares gain another 2% as SunTrust raises stock price target to $178 vs. $116 MarketWatch
06:56AM  Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug MarketWatch
Dec-07-17 06:00PM  Why Sage Therapeutics Gained 70% Today Motley Fool +70.04%
05:05PM  What Happened in the Stock Market Today Motley Fool
05:02PM  Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference Business Wire
04:32PM  Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday Motley Fool
04:24PM  Sage Therapeutics, Dollar General jump; LendingClub tumbles Associated Press
04:08PM  This Biotech Catapults 70% Higher On Depression Drug Results Investor's Business Daily
04:06PM  3 Stocks Gain on Thursday
03:52PM  Sage soars on mid-phase depression drug trial CNBC Videos
02:41PM  Cowen Raises Sage Value On New Phase 2 Trial Success Benzinga
02:10PM  Sage Therapeutics Rises 70% on Strong Phase 2 Results
12:57PM  Charting the Market: Sage Therapeutics Could Cure Your Blues
10:55AM  With latest drug trial, Sage catapults into top 5 most valuable Mass. biotechs American City Business Journals
09:55AM  SAGE Therapeutics Inc (SAGE) Shines on Encouraging Clinical Data SmarterAnalyst
09:26AM  Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers
09:11AM  UPDATE: Sage Therapeutics shares soar more than 74% on positive trial of depression treatment MarketWatch
09:03AM  Biotech Sage Therapeutics skyrockets more than 70 percent after depression drug breakthrough CNBC
08:42AM  Stocks making the biggest moves premarket: SHAK, AVGO, EXPE, PCLN & more CNBC
06:42AM  Sage's depression drug succeeds in mid-stage study, shares soar Reuters
06:19AM  Sage's depression drug succeeds in mid-stage study Reuters
06:00AM  Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder Business Wire
Dec-04-17 04:01PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
08:05AM  Factors of Influence in 2018, Key Indicators and Opportunity within Exelon, Newell Brands, Sage Therapeutics, Advanced Disposal Services, Opus Bank, and Anworth Mortgage Asset New Research Emphasizes Economic Growth GlobeNewswire
Nov-30-17 03:38PM  SAGE Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube
Nov-22-17 08:00AM  Todays Research Reports on Stocks to Watch: Sage Therapeutics and GW Pharmaceuticals ACCESSWIRE +6.12%
Nov-17-17 04:01PM  Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares Business Wire
02:43PM  Why Biotech Sage Therapeutics Is Overvalued Investopedia
Nov-14-17 09:00PM  Sage Therapeutics Prices Public Offering of Common Stock Business Wire -6.76%
03:03PM  7 Life Science Stocks to Buy Today InvestorPlace
Nov-13-17 04:01PM  Sage Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Nov-11-17 03:15PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Nov-10-17 03:05PM  Likely FDA approval for postpartum depression drug pushes Sage Therapeutics stock up 40% CNBC
01:35PM  Sage Therapeutics takes on postpartum depression with tri... CNBC Videos
08:10AM  Todays Research Reports on Stocks to Watch: Aralez Pharmaceuticals and Sage Therapeutics ACCESSWIRE
06:56AM  Sage Therapeutics stock bounces 54% after positive results for depression treatment MarketWatch
Nov-09-17 05:36PM  Sage Therapeutics Hits Record On Potential $600 Million Depression Drug Investor's Business Daily +54.25%
12:40PM  2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why. Motley Fool
10:03AM  New Drug Eases Postpartum Depression In Victory For Tiny Sage Therapeutics Forbes
09:30AM  Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers
07:09AM  Sage Therapeutics stock surges 50% on positive trial results in postpartum depression MarketWatch
06:51AM  Sage Therapeutics to seek approval of postpartum depression drug after trial win American City Business Journals
06:31AM  Sage Therapeutics postpartum depression drug meets goal in two trials Reuters
06:00AM  Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression Business Wire
Nov-08-17 07:00AM  Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors Business Wire
Nov-06-17 07:50AM  Report: Developing Opportunities within Abaxis, PRA Health Sciences, Brighthouse, Investors Bancorp, Cypress Semiconductor, and Sage Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire -5.20%
Nov-03-17 07:00AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire +10.42%
Nov-02-17 01:46PM  Edited Transcript of SAGE earnings conference call or presentation 2-Nov-17 12:00pm GMT Thomson Reuters StreetEvents
06:41AM  Sage Therapeutics reports 3Q loss Associated Press
06:30AM  Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update Business Wire
06:05AM  SAGE Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-26-17 08:33AM  Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options Zacks
Oct-24-17 08:00AM  Sage Therapeutics to Report Third Quarter 2017 Financial Results on Thursday, November 2, 2017 Business Wire
Oct-05-17 12:20AM  Edited Transcript of SAGE earnings conference call or presentation 3-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Oct-02-17 02:00PM  3 Beaten-Down Biotech Stocks to Buy Right Now Motley Fool
Sep-22-17 04:05PM  Sage Therapeutics to Participate in Leerink Investor Conference Business Wire
08:30AM  Implied Volatility Surging for Sage Therapeutics, Inc. (SAGE) Stock Options Zacks
Sep-15-17 03:39PM  What Analysts Recommend for Sage Therapeutics Market Realist
02:06PM  Sage Therapeutics Could Still Become A Leader In Neurology Benzinga
01:56PM  What to Expect from Sage Therapeutics Brexanolone Market Realist
Sep-14-17 07:50AM  Corporate News Blog - Sage Therapeutics Announces Top-Line Results from Phase-3 STATUS Trial of Brexanolone ACCESSWIRE -7.84%
Sep-13-17 08:42AM  Sage Therapeutics drug for rare condition deemed a failure, but company may see a path forward MarketWatch -7.89%
Sep-12-17 06:30PM  Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy? Motley Fool -13.69%
04:56PM  Alexion Could Target Sage, Ra Pharma: Analyst
04:10PM  Sage Dives On Seizure Trial, But Could Double On Depression Drugs Investor's Business Daily
03:36PM  The Biggest Drop in More Than a Year
02:49PM  Biotech: When Good Drugs Go Bad
02:00PM  Sage Shows Why There Are Rules for Drug Development Bloomberg
11:19AM  Is Sage Therapeutics Inc (SAGE) Undervalued? Simply Wall St.
10:20AM  Sage Therapeutics Gets a Dunce Hat 24/7 Wall St.
10:08AM  Trial fail for Cambridge-based Sage casts doubt on lead drug American City Business Journals
09:52AM  US STOCKS-S&P opens at record high as Irma weakens; Apple in focus Reuters
08:58AM  US STOCKS-Wall St set to open higher as Irma weakens; Apple in focus Reuters
07:57AM  Sage Therapeutics' stock sinks after disappointing late-stage trial of SRSE treatment MarketWatch
06:16AM  Sage's seizure disorder drug fails late-stage trial Reuters
06:00AM  Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus Business Wire
Sep-07-17 04:05PM  Sage Therapeutics to Present at Morgan Stanley Healthcare Conference Business Wire
Sep-06-17 04:05PM  Brexanolone Could Strengthen Ligands Neurology Portfolio Market Realist
04:05PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-28-17 08:41AM  Options Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock Zacks
Aug-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Sage Therapeutics ACCESSWIRE
Aug-03-17 04:01PM  Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update Business Wire
12:10PM  Investor Network: SAGE Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Jul-20-17 04:10PM  Sage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017 Business Wire
Jul-10-17 04:10PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-14-17 10:35AM  UNC working with Mass. pharma company on depression drug American City Business Journals
Jun-12-17 06:41PM  Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression Business Wire
Jun-08-17 04:01PM  Sage Therapeutics to Present at Goldman Sachs Healthcare Conference Business Wire
Jun-05-17 07:00AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-18-17 09:57AM  Biotech Movers: Fast Track Designation Sends Sage Shares Higher
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The company's product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinson's diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Robichaud AlbertChief Scientific OfficerDec 14Sale159.4360,0009,565,95794,259Dec 14 06:51 PM
IGUCHI KIMICFO, Secretary and TreasurerJan 13Sale53.9210,000539,20066,498Jan 13 03:51 PM